From compliance to circularity: Three ways pharma manufacturers can rethink resource management

Access to medication and clean water is a balancing act. As the production and access to medication grow, a new set  of water-related challenges presents itself, such as antimicrobial resistance, ecotoxicity, and emerging contaminants  including residual active pharmaceutical ingredients (APIs), and endocrine disrupting chemicals (EDCs) in surface  waters, groundwater, soil, drinking water, or even within the food chain.  For pharmaceutical companies looking to improve their environmental, social and governance (ESG) performance,  effective water management within manufacturing processes can serve as a strategic lever to translate typical  challenges into opportunities for environmental sustainability and business resilience. Here are some areas that  decision-makers can consider:   Water quality and process resilience   Water is deeply embedded in pharmaceutical manufacturing—not only as a utility, but as a critical raw material  used across production, formulation, dilution, cleaning, and rinsing processes. Depending on the application,  water demand can be substantial: in some cases, producing a single ton of active ingredient may require  hundreds of cubic metres of water across production and cleaning operations.  This reliance creates a unique operational challenge. Because water readily dissolves, absorbs, and transports  contaminants, maintaining consistent quality standards becomes essential—not just for regulatory compliance,  but for process integrity and product safety. Most pharmacopeias therefore require pharmaceutical  manufacturers to begin with drinking water and further purify it to application-specific standards, such as  purified water or water for injection (WFI).  For pharmaceutical manufacturers, water security has become a strategic imperative—not merely an  environmental consideration, but a fundamental pillar of operational resilience and long-term business viability.  As a result, pharmaceutical manufacturers devote significant resources to water purification, microbiological  control, and the maintenance of highly controlled water systems. In an industry where water quality directly  affects both product quality and operational continuity, pharmaceutical water control is a continuous, dynamic  process, rather than a static checkpoint.   Water consumption and reuse   Water reclamation and reuse are becoming more compelling as rising raw water and discharge tariffs narrow  the cost gap between recycled and fresh water. API manufacturing facilities that generate larger volumes of  wastewater with lower contaminant levels could recycle water for cooling towers, washing applications, and  other ancillary needs.   Digital monitoring capabilities are also accelerating the adoption of water reuse initiatives. AI-driven predictive  maintenance flags membrane degradation and system wear before it affects performance, while online  microbial analysis gives operators real-time contamination visibility.   Together, these tools give operators a clearer picture of water and wastewater treatment processes, enabling  informed decisions about optimising water consumption. They also support a more connected view of  operations, where water performance is considered alongside energy use and overall process efficiency. Water  reuse and recycling will increasingly become an essential pillar for the long-term viability of operations.  Solvent recovery   Spent solvents can constitute between 50-80 per cent of the waste of a chemical API plant, and up to 40 per cent of these  solvents can be regenerated through innovative volatile organic chemicals (VOC) treatment technologies.  Recovered solvents can re-enter production or be sold to third parties—converting what was a disposal cost  into a revenue stream. Technologies capable of achieving these recovery rates are well-established and  deployable at API manufacturing scale.  Maximising these benefits often depends on how recovery processes are integrated with existing production  and waste handling systems, ensuring that efficiencies gained in one area do not introduce trade-offs in  another.  By approaching these three areas as an integrated system rather than separate compliance tasks, manufacturers can  convert typical challenges into tangible sustainability and commercial gains.  Looking beyond individual treatment technologies—to how water, waste, and energy systems interact across an  operation—is where that integration becomes most effective. When these capabilities are brought together,  manufacturers gain a more precise and resilient response to both operational demands and environmental pressures,  safeguarding critical resources and supporting environmental security for manufacturers and the communities they  operate in alike.  These topics will be explored further in a masterclass series by Veolia for pharmaceutical professionals, with a focus on  building water security and operational resilience through integrated approaches to GMP design, microbial control,  validation, and wastewater management. More information and registration details are available here:  https://go.watertechnologies.com/Pharmaceutical-Masterclass-RP.html  The post From compliance to circularity: Three ways pharma manufacturers can rethink resource management appeared first on Express Pharma.